Please enable JavaScript to continue using this application.

Compare tickers

Valuation, margins, and growth side by side.

Compare $KYMR vs $TGTX | Chartloom

Compare

$KYMR vs $TGTX

Kymera Therapeutics Inc · TG Therapeutics Inc

KYMR

Kymera Therapeutics Inc

TGTX

TG Therapeutics Inc

Compare $KYMR vs $TGTX

Comparing Kymera Therapeutics Inc and TG Therapeutics Inc

KYMRKymera Therapeutics Inc

TGTXTG Therapeutics Inc

KYMRKymera Therapeutics Inc

Market cap

$8.78B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

433.66x

Rev growth (TTM)

134.8%

YTD performance

46.6%

52W performance

86.5%

FCF yield

-2.7%

TGTXTG Therapeutics Inc

Market cap

$8.32B

P/E (TTM)

19.36x

Forward P/E (NTM)

27.77x

Forward P/S (NTM)

7.37x

Rev growth (TTM)

76.1%

YTD performance

85.6%

52W performance

61.0%

FCF yield

0.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

KYMR

TGTX

Detailed metrics comparison

KYMR

Kymera Therapeutics Inc

TGTX

TG Therapeutics Inc

Market Cap

KYMR$8.78B

TGTX$8.32B

Enterprise Value

KYMR$8.65B

TGTX$8.58B

Price

KYMR$106.68

TGTX$54.34

P/E Ratio

KYMRN/A

TGTX19.36x

P/S Ratio

KYMR83.58x

TGTX10.40x

EV/Sales

KYMR82.41x

TGTX10.73x

EV/EBITDA

KYMR0.00x

TGTX61.91x

P/B Ratio

KYMR6.19x

TGTX14.03x

P/FCF Ratio

KYMRN/A

TGTX478.48x

EV/FCF

KYMR-36.37x

TGTX493.60x

PEG Ratio

KYMRN/A

TGTX0.83x

Forward P/E (NTM)

KYMRN/A

TGTX27.77x

Forward P/S (NTM)

KYMR433.66x

TGTX7.37x

Revenue (TTM)

KYMR$105M

TGTX$800M

Revenue Growth (YoY)

KYMR134.8%

TGTX76.1%

Forward Rev Growth

KYMR-62.1%

TGTX35.6%

Gross Margin (TTM)

KYMR0.0%

TGTX82.4%

Operating Margin (TTM)

KYMR0.0%

TGTX15.9%

EBITDA Margin (TTM)

KYMR-322.0%

TGTX17.1%

Net Margin (TTM)

KYMR-285.3%

TGTX55.2%

FCF Margin (TTM)

KYMR-226.6%

TGTX2.2%

Net Income (TTM)

KYMR$-300M

TGTX$441M

FCF (TTM)

KYMR$-238M

TGTX$17M

EPS (TTM)

KYMR-$3.05

TGTX$2.81

ROE (TTM)

KYMR-2150.0%

TGTX72.3%

ROA (TTM)

KYMR-1946.0%

TGTX33.6%

ROIC (TTM)

KYMR-2145.0%

TGTX39.9%

Cash

KYMR$124M

TGTX$483M

Debt

KYMR$2M

TGTX$745M

Net Cash/Debt

KYMR$122M

TGTX$-263M

Current Ratio (TTM)

KYMR10.34x

TGTX4.27x

Quick Ratio (TTM)

KYMR9.97x

TGTX3.72x

Debt/Equity (TTM)

KYMR0.00x

TGTX1.23x

Debt/Assets (TTM)

KYMR0.0%

TGTX0.0%

Interest Coverage (TTM)

KYMRN/A

TGTXN/A

Net Debt/EBITDA (TTM)

KYMR0.00x

TGTX0.00x

Beta

KYMR2.04

TGTX1.82

52W Performance

KYMR86.5%

TGTX61.0%

YTD Performance

KYMR46.6%

TGTX85.6%

% from 52W High

KYMR-18.0%

TGTX-8.4%

% from 52W Low

KYMR93.1%

TGTX103.1%

Asset Turnover (TTM)

KYMR0.07x

TGTX0.61x

FCF Yield (TTM)

KYMR-2.7%

TGTX0.2%

Earnings Yield (TTM)

KYMR-3.4%

TGTX5.3%

Dividend Yield (TTM)

KYMRN/A

TGTXN/A

Rule of 40

KYMR-91.8

TGTX78.3

EV/GP/RG

KYMRN/A

TGTX0.31

Ticker research

View KYMR research View TGTX research

Metric	KYMR Kymera Therapeutics Inc	TGTX TG Therapeutics Inc
Market & Valuation
Market Cap	$8.78B	$8.32B
Enterprise Value	$8.65B	$8.58B
Price	$106.68	$54.34
P/E Ratio	N/A	19.36x
P/S Ratio	83.58x	10.40x
EV/Sales	82.41x	10.73x
EV/EBITDA	0.00x	61.91x
P/B Ratio	6.19x	14.03x
P/FCF Ratio	N/A	478.48x
EV/FCF	-36.37x	493.60x
PEG Ratio	N/A	0.83x
Forward P/E (NTM)	N/A	27.77x
Forward P/S (NTM)	433.66x	7.37x
Revenue & Growth
Revenue (TTM)	$105M	$800M
Revenue Growth (YoY)	134.8%	76.1%
Forward Rev Growth	-62.1%	35.6%
Profitability
Gross Margin (TTM)	0.0%	82.4%
Operating Margin (TTM)	0.0%	15.9%
EBITDA Margin (TTM)	-322.0%	17.1%
Net Margin (TTM)	-285.3%	55.2%
FCF Margin (TTM)	-226.6%	2.2%
Net Income (TTM)	$-300M	$441M
FCF (TTM)	$-238M	$17M
EPS (TTM)	-$3.05	$2.81
ROE (TTM)	-2150.0%	72.3%
ROA (TTM)	-1946.0%	33.6%
ROIC (TTM)	-2145.0%	39.9%
Financial Health
Cash	$124M	$483M
Debt	$2M	$745M
Net Cash/Debt	$122M	$-263M
Current Ratio (TTM)	10.34x	4.27x
Quick Ratio (TTM)	9.97x	3.72x
Debt/Equity (TTM)	0.00x	1.23x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.04	1.82
52W Performance	86.5%	61.0%
YTD Performance	46.6%	85.6%
% from 52W High	-18.0%	-8.4%
% from 52W Low	93.1%	103.1%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.61x
FCF Yield (TTM)	-2.7%	0.2%
Earnings Yield (TTM)	-3.4%	5.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-91.8	78.3
EV/GP/RG	N/A	0.31
Ticker research	View KYMR research	View TGTX research

Valuation

P/E Ratio

TGTX

19.36x

P/S Ratio

TGTX

10.40x

KYMR

83.58x

EV/FCF

KYMR

-36.37x

TGTX

493.60x

Growth & revenue

Revenue Growth TTM

KYMR

134.8%

TGTX

76.1%

Forward Revenue Growth

TGTX

35.6%

KYMR

-62.1%

Profitability & performance

Gross Margin

TGTX

82.4%

KYMR

0.0%

ROE

TGTX

72.3%

KYMR

-2150.0%

FCF Yield %

TGTX

0.2%

KYMR

-2.7%

52-Week Performance

KYMR

86.5%

TGTX

61.0%

Detailed metrics comparison

KYMR

Kymera Therapeutics Inc

TGTX

TG Therapeutics Inc

Market Cap

KYMR$8.78B

TGTX$8.32B

Enterprise Value

KYMR$8.65B

TGTX$8.58B

Price

KYMR$106.68

TGTX$54.34

P/E Ratio

KYMRN/A

TGTX19.36x

P/S Ratio

KYMR83.58x

TGTX10.40x

EV/Sales

KYMR82.41x

TGTX10.73x

EV/EBITDA

KYMR0.00x

TGTX61.91x

P/B Ratio

KYMR6.19x

TGTX14.03x

P/FCF Ratio

KYMRN/A

TGTX478.48x

EV/FCF

KYMR-36.37x

TGTX493.60x

PEG Ratio

KYMRN/A

TGTX0.83x

Forward P/E (NTM)

KYMRN/A

TGTX27.77x

Forward P/S (NTM)

KYMR433.66x

TGTX7.37x

Revenue (TTM)

KYMR$105M

TGTX$800M

Revenue Growth (YoY)

KYMR134.8%

TGTX76.1%

Forward Rev Growth

KYMR-62.1%

TGTX35.6%

Gross Margin (TTM)

KYMR0.0%

TGTX82.4%

Operating Margin (TTM)

KYMR0.0%

TGTX15.9%

EBITDA Margin (TTM)

KYMR-322.0%

TGTX17.1%

Net Margin (TTM)

KYMR-285.3%

TGTX55.2%

FCF Margin (TTM)

KYMR-226.6%

TGTX2.2%

Net Income (TTM)

KYMR$-300M

TGTX$441M

FCF (TTM)

KYMR$-238M

TGTX$17M

EPS (TTM)

KYMR-$3.05

TGTX$2.81

ROE (TTM)

KYMR-2150.0%

TGTX72.3%

ROA (TTM)

KYMR-1946.0%

TGTX33.6%

ROIC (TTM)

KYMR-2145.0%

TGTX39.9%

Cash

KYMR$124M

TGTX$483M

Debt

KYMR$2M

TGTX$745M

Net Cash/Debt

KYMR$122M

TGTX$-263M

Current Ratio (TTM)

KYMR10.34x

TGTX4.27x

Quick Ratio (TTM)

KYMR9.97x

TGTX3.72x

Debt/Equity (TTM)

KYMR0.00x

TGTX1.23x

Debt/Assets (TTM)

KYMR0.0%

TGTX0.0%

Interest Coverage (TTM)

KYMRN/A

TGTXN/A

Net Debt/EBITDA (TTM)

KYMR0.00x

TGTX0.00x

Beta

KYMR2.04

TGTX1.82

52W Performance

KYMR86.5%

TGTX61.0%

YTD Performance

KYMR46.6%

TGTX85.6%

% from 52W High

KYMR-18.0%

TGTX-8.4%

% from 52W Low

KYMR93.1%

TGTX103.1%

Asset Turnover (TTM)

KYMR0.07x

TGTX0.61x

FCF Yield (TTM)

KYMR-2.7%

TGTX0.2%

Earnings Yield (TTM)

KYMR-3.4%

TGTX5.3%

Dividend Yield (TTM)

KYMRN/A

TGTXN/A

Rule of 40

KYMR-91.8

TGTX78.3

EV/GP/RG

KYMRN/A

TGTX0.31

Ticker research

View KYMR research View TGTX research

Metric	KYMR Kymera Therapeutics Inc	TGTX TG Therapeutics Inc
Market & Valuation
Market Cap	$8.78B	$8.32B
Enterprise Value	$8.65B	$8.58B
Price	$106.68	$54.34
P/E Ratio	N/A	19.36x
P/S Ratio	83.58x	10.40x
EV/Sales	82.41x	10.73x
EV/EBITDA	0.00x	61.91x
P/B Ratio	6.19x	14.03x
P/FCF Ratio	N/A	478.48x
EV/FCF	-36.37x	493.60x
PEG Ratio	N/A	0.83x
Forward P/E (NTM)	N/A	27.77x
Forward P/S (NTM)	433.66x	7.37x
Revenue & Growth
Revenue (TTM)	$105M	$800M
Revenue Growth (YoY)	134.8%	76.1%
Forward Rev Growth	-62.1%	35.6%
Profitability
Gross Margin (TTM)	0.0%	82.4%
Operating Margin (TTM)	0.0%	15.9%
EBITDA Margin (TTM)	-322.0%	17.1%
Net Margin (TTM)	-285.3%	55.2%
FCF Margin (TTM)	-226.6%	2.2%
Net Income (TTM)	$-300M	$441M
FCF (TTM)	$-238M	$17M
EPS (TTM)	-$3.05	$2.81
ROE (TTM)	-2150.0%	72.3%
ROA (TTM)	-1946.0%	33.6%
ROIC (TTM)	-2145.0%	39.9%
Financial Health
Cash	$124M	$483M
Debt	$2M	$745M
Net Cash/Debt	$122M	$-263M
Current Ratio (TTM)	10.34x	4.27x
Quick Ratio (TTM)	9.97x	3.72x
Debt/Equity (TTM)	0.00x	1.23x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.04	1.82
52W Performance	86.5%	61.0%
YTD Performance	46.6%	85.6%
% from 52W High	-18.0%	-8.4%
% from 52W Low	93.1%	103.1%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.61x
FCF Yield (TTM)	-2.7%	0.2%
Earnings Yield (TTM)	-3.4%	5.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-91.8	78.3
EV/GP/RG	N/A	0.31
Ticker research	View KYMR research	View TGTX research